| NCT07181382 | Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | NOT_YET_RECRUITING | PHASE3 | 2025-12 | 2028-12 | 2028-12 |
| NCT06274801 | Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | RECRUITING | PHASE3 | 2024-09-03 | 2026-12 | 2026-12 |
| NCT05934526 | Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-12-28 | 2025-12 | 2025-11 |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma | TERMINATED | PHASE1 | 2022-05-24 | 2023-05-11 | 2023-05-11 |
| NCT04816604 | Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | ACTIVE_NOT_RECRUITING | PHASE2 | 2021-04-05 | 2027-12 | 2027-12 |
| NCT04456998 | GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) | COMPLETED | PHASE2 | 2020-11-12 | 2022-11-01 | 2022-10-17 |
| NCT04556383 | A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC) | TERMINATED | PHASE2 | 2020-10-19 | 2022-06-01 | 2022-06-01 |
| NCT03926793 | Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension | COMPLETED | PHASE1 | 2020-02-04 | 2021-05-05 | 2021-05-05 |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | TERMINATED | PHASE1 | 2019-08-13 | 2022-04-11 | 2022-04-11 |
| NCT03956862 | GB001 in Adult Participants With Chronic Rhinosinusitis | COMPLETED | PHASE2 | 2019-05-16 | 2020-08-05 | 2020-07-09 |
| NCT03860896 | GB004 in Adult Subjects With Active Ulcerative Colitis | COMPLETED | PHASE1 | 2019-04-24 | 2019-12-17 | 2019-12-17 |
| NCT03683576 | GB001 in Adult Subjects With Moderate to Severe Asthma | COMPLETED | PHASE2 | 2018-10-22 | 2020-08-18 | 2020-07-23 |
| NCT03473236 | Phase 1A Safety Trial of Inhaled PK10571 (GB002) | COMPLETED | PHASE1 | 2017-09-06 | 2018-12-03 | 2018-12-03 |